Enzalutamide in metastatic prostate cancer before chemotherapy (Q34422206)

2 August 2017

Enzalutamide in metastatic prostate cancer before chemotherapy (English)

1 reference

2 August 2017

1 reference

1 reference

Dana E Rathkopf

3

0 references

Anthony M Joshua

Anthony M Joshua

15

0 references

Go Kimura

Go Kimura

17

0 references

Joan Carles Galcerán

Joan Carles

9

0 references

Karim Fizazi

14

Karim Fizazi

1 reference

2 August 2017

26

Mary-Ellen Taplin

1 reference

2 August 2017

24

Fred Saad

1 reference

2 August 2017

16

Choung-Soo Kim

1 reference

2 August 2017

Tomasz M Beer

1

1 reference

2 August 2017

Andrew J Armstrong

2

1 reference

2 August 2017

Yohann Loriot

4

1 reference

2 August 2017

Cora N Sternberg

5

1 reference

2 August 2017

Celestia S Higano

6

1 reference

2 August 2017

Peter Iversen

7

1 reference

2 August 2017

Suman Bhattacharya

8

1 reference

2 August 2017

Simon Chowdhury

10

1 reference

2 August 2017

Ian D Davis

11

1 reference

2 August 2017

Johann S de Bono

12

1 reference

2 August 2017

Christopher P Evans

13

1 reference

2 August 2017

Paul Mainwaring

18

1 reference

2 August 2017

Harry Mansbach

19

1 reference

2 August 2017

Kurt Miller

20

1 reference

2 August 2017

Sarah B Noonberg

21

1 reference

2 August 2017

Frank Perabo

22

1 reference

2 August 2017

De Phung

23

1 reference

2 August 2017

Howard I Scher

25

1 reference

2 August 2017

Peter M Venner

27

1 reference

2 August 2017

Bertrand Tombal

28

1 reference

2 August 2017

PREVAIL Investigators

29

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 June 2014

1 reference

The New England Journal of Medicine

2 August 2017

1 reference

2 August 2017

371

1 reference

2 August 2017

5

1 reference

2 August 2017

424-433

1 reference

Alpha emitter radium-223 and survival in metastatic prostate cancer

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Population-based study on use of chemotherapy in men with castration resistant prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Abiraterone in metastatic prostate cancer without previous chemotherapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Increased survival with enzalutamide in prostate cancer after chemotherapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Targeting continued androgen receptor signaling in prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Abiraterone and increased survival in metastatic prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

6 July 2018

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Molecular determinants of resistance to antiandrogen therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follo

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418931

A population-based study of prostate cancer chemotherapy

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24881730

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24881730

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1405095

1 reference

2 August 2017

1 reference

2 August 2017

1 reference